IRLAB Therapeutics
1.60 SEK
+0.38 %
Less than 1K followers
IRLAB A
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for IRLAB Therapeutics
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 207.8 | 61.1 | 5.7 | 94.6 | 57.5 | |
| growth-% | -70.6 % | -90.7 % | 1,566.0 % | -39.3 % | |||
| EBITDA | -92.9 | -89.2 | 56.1 | -108.3 | -176.5 | -70.5 | -89.1 |
| EBIT | -95.8 | -91.5 | 52.6 | -113.1 | -180.8 | -75.1 | -93.4 |
| Profit before taxes | -96.1 | -91.7 | 51.8 | -113.4 | -177.8 | -83.1 | -110.0 |
| Net income | -96.1 | -91.7 | 51.8 | -113.4 | -177.8 | -83.1 | -110.0 |
| EPS | -2.20 | -1.81 | 0.94 | -2.07 | -3.24 | -1.51 | -1.64 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | 0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -357,373.1 % | 27.0 % | -177.2 % | -3,106.5 % | -74.5 % | -155.0 % | |
| EBIT-% | -368,646.2 % | 25.3 % | -185.0 % | -3,182.6 % | -79.4 % | -162.5 % | |
| ROE | -52.9 % | -26.3 % | 13.0 % | -39.0 % | -153.6 % | -254.7 % | -358.1 % |
| ROI | -46.2 % | -24.8 % | 11.0 % | -35.1 % | -100.4 % | -61.0 % | -79.6 % |